Zoetis Inc. Other Significant Noncash Transaction, Value of Consideration Given
Zoetis Inc. (ZTS) reported Other Significant Noncash Transaction, Value of Consideration Given of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2022-02-15
- Zoetis Inc. other significant noncash transaction, value of consideration given for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Zoetis Inc. other significant noncash transaction, value of consideration given for the quarter ending 2017-12-31 was $29.00M.
- Zoetis Inc. other significant noncash transaction, value of consideration given for the quarter ending 2017-10-01 was $0.00, a 100.00% decline year-over-year.
- Zoetis Inc. other significant noncash transaction, value of consideration given for the quarter ending 2017-07-02 was -$2.00M.
- Zoetis Inc. other significant noncash transaction, value of consideration given for fiscal 2021 was $0.00.
- Zoetis Inc. other significant noncash transaction, value of consideration given for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Zoetis Inc. other significant noncash transaction, value of consideration given for fiscal 2019 was $23.00M.
- Zoetis Inc. other significant noncash transaction, value of consideration given for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-15 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-15 | |||
| 2019-12-31 | $23.00M 10-K · filed 2022-02-15 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-02 | $29.00M derived: sum of 2 quarters · filed 2020-02-13 | $29.00M derived: sum of 3 quarters · filed 2020-02-13 | $27.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $29.00M derived: sum of 2 quarters · filed 2020-02-13 | $27.00M derived: sum of 3 quarters · filed 2020-02-13 | $29.00M 10-K · filed 2020-02-13 |
| 2017-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$2.00M derived: sum of 2 quarters · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | -$2.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-07-02 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $0.00 10-Q · filed 2017-08-08 | -$2.00M derived: sum of 3 quarters · filed 2019-02-14 | $0.00 derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-04-02 | $2.00M 10-Q · filed 2018-05-02 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $2.00M derived: sum of 3 quarters · filed 2019-02-14 | $2.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 derived: sum of 3 quarters · filed 2019-02-14 | $27.00M 10-K · filed 2019-02-14 |
| 2016-10-02 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $2.00M derived: sum of 2 quarters · filed 2017-11-02 | $29.00M 10-Q · filed 2017-11-02 | $30.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-07-03 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $27.00M 10-Q · filed 2017-08-08 | $28.00M derived: sum of 3 quarters · filed 2018-02-15 | $28.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-04-03 | $27.00M 10-Q · filed 2017-05-04 | $28.00M derived: sum of 2 quarters · filed 2018-02-15 | $28.00M derived: sum of 3 quarters · filed 2018-02-15 | $28.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.00M derived: sum of 2 quarters · filed 2018-02-15 | $1.00M derived: sum of 3 quarters · filed 2018-02-15 | $23.00M 10-K · filed 2018-02-15 |
| 2015-09-27 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $22.00M 10-Q · filed 2016-11-03 | $22.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $22.00M 10-Q · filed 2016-08-05 | $22.00M derived: sum of 3 quarters · filed 2017-02-16 | $22.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-29 | $22.00M 10-Q · filed 2016-05-06 | $22.00M derived: sum of 2 quarters · filed 2017-02-16 | $22.00M derived: sum of 3 quarters · filed 2017-02-16 | $22.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $0.00 derived: sum of 2 quarters · filed 2017-02-16 | $0.00 derived: sum of 3 quarters · filed 2017-02-16 | $0.00 10-K · filed 2017-02-16 |
| 2014-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | |
| 2014-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | ||
| 2014-03-30 | $0.00 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | $3.00M 10-K · filed 2016-02-24 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |